Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Monetary Strengthening: Assuming Command over Your Cash - 2US students studying housing, health outcomes and sustainability win 2026 Rhodes scholarships
- 3December's overlooked meteor shower peaks next week — will the Ursids surprise us?
- 4Step by step instructions to Choose the Right Auto Crash Legal counselor for Your Case
- 5Do-It-Yourself Home Style on a Careful spending plan: Imaginative Thoughts and Tasks
- Figure out How to Protect Your Gold Venture from Unpredictability
- Moderna to complete US mRNA manufacturing network with $140 million investment
- Last Christmas, 3 million viewers watched a Chiefs love story — will Bills fans fall just as hard this year?
- A Manual for SUVs with Less Noteworthy Gas Mileage
- The Best Internet based Courses for Expertise Improvement
- Lilly becomes first healthcare firm to join trillion-dollar club, Wall Street reacts
- Many European nations want Israel to cancel 19 new settlement plans
- Triple polar vortex to plunge central and eastern U.S. into Arctic cold through mid-December
- 6 Nations for Setting up camp
